Canaccord Genuity Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $36
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni has initiated coverage on Annovis Bio with a Buy rating and set a price target of $36. The company is listed on the NYSE under the ticker ANVS.
December 29, 2023 | 10:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has initiated coverage on Annovis Bio with a Buy rating and a price target of $36, which may positively influence the stock's performance in the short term.
Analyst ratings, especially from reputable firms like Canaccord Genuity, can significantly impact a stock's performance. A Buy rating combined with a high price target suggests a strong positive outlook for Annovis Bio, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100